TITLE

In this issue

PUB. DATE
November 2010
SOURCE
Nature Reviews Drug Discovery;Nov2010, Vol. 9 Issue 11, p821
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses various reports published within the issue, including one by Brinkmann and colleagues on the case history of fingolimod, one by Cohen on cyclical development strategy, and one by Doroshow and colleagues on their evaluation of anticancer agents at the U.S. National Cancer Institute.
ACCESSION #
54874823

 

Related Articles

  • Fresh from the pipeline: Gefitinib. Muhsin, Mohamed; Graham, Joanne; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jul2003, Vol. 2 Issue 7, p515 

    Gefitinib (Iressa; AstraZeneca) is the first in a new class of targeted anticancer drugs that inhibit the tyrosine kinase activity of the epidermal growth factor receptor. Following Japanese approval in 2002, gefitinib was approved by the US FDA in May 2003 for the treatment of advanced...

  • Anticancer chemotherapy. Davey, Peter; Tudhope, G.R. // British Medical Journal (Clinical Research Edition);7/9/1983, Vol. 287 Issue 6385, p107 

    Features several of the latest cytotoxic drugs and its applications in Great Britain. Current drugs and their analogues; Developments with antimetabolites; Enumerations on latest cytotoxic drugs.

  • Current Targets for Anticancer Drug Discovery. N-H. Nam; K. Parang // Current Drug Targets;Feb2003, Vol. 4 Issue 2, p159 

    The call for the discovery of less toxic, more selective, and more effective agents to treat cancer has become more urgent. Inhibition of angiogenesis continues to be one of the main streams in the current cancer drug discovery activity. Insights into tumor angiogenesis biology have led to the...

  • Human tyrosyl-DNA phosphodiesterase 1: new activities and development of enzyme inhibitors as anticancer drugs. Lavrik, O. // Biopolymers & Cell;2015 Suppl. 5, p13 

    Tyrosyl-DNA phosphodiesterase 1 (TDP1) is responsible to process topoisomerase 1 (TOP1) - DNA adducts as well as to hydrolyze a variety of other DNA 3'-substituents. We have shown recently that TDP1 can initiate repair of apurinic/apyrimidinic (AP) sites located in the internal positions of DNA...

  • Formation of platinated GG cross-links on DNA by photoactivation of a platinum(IV) azide complex. Jana Ka?párková; Fiona S. Mackay; Viktor Brabec; Peter J. Sadler // Journal of Biological Inorganic Chemistry;Sep2003, Vol. 8 Issue 7, p741 

    Platinum(II) diam(m)ine complexes such as cisplatin are effective anticancer drugs but have accompanying side effects. We are exploring the design of platinum complexes with low toxicity that could be photoactivated selectively at the target site. We show here that the Pt(IV) azide complex cis,...

  • Targeting cancer stem cells. Feliciano, Pamela // Nature Genetics;Jul2012, Vol. 44 Issue 7, p739 

    The article focuses on the efforts to develop drugs that selectively target cancer stem cells which bear cancers.

  • Wondering What You Missed in BioWorld Insight?  // BioWorld Today;5/30/2012, p7 

    The article presents an overview of the reports in "BioWorld Insight" journal, including a report which explored the technologies that are making undruggable targets accessible to therapeutic intervention and the withdrawal of lung cancer drug Iressa (gefitinib) in the U.S.

  • DNA Tetraplex-Binding Drugs Structure-Selective Targeting is Critical for Antitumour Telomerase Inhibition. Perry, Philip J.; Jenkins, Terence C. // Mini Reviews in Medicinal Chemistry;May2001, Vol. 1 Issue 1, p31 

    Four-stranded tetraplex (“G-quadruplex”) DNA represents a new paradigm for the design of DNA-interactive antitumour drugs, as the formed DNA-drug complexes have been suggested to interfere with critical telomerase function. The unique structural features presented by tetraplex over...

  • Recent Progress in the Development of Anticancer Agents. Sandor Eckhardt // Current Medicinal Chemistry - Anti-Cancer Agents;May2002, Vol. 2 Issue 3, p419 

    Cancer chemotherapy started with the discovery of the cytostatic effect of N-mustard and its derivatives more than five decades ago. This observation opened the way for the synthesis of various alkylating agents, antimetabolites and antimitotics expliciting antitumour activity against several...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics